SCHEDULE: Vivos Therapeutics Stakeholder Discloses Significant Ownership

Sentiment:

Schedule 13D Filing 15 July 2026 5:07 PM

📋All filings for Vivos Therapeutics, INC

A group of investment entities and their manager have disclosed a significant beneficial ownership stake in Vivos Therapeutics, Inc., totaling 19.9% as of July 15, 2026.

Capital raiseV-Co 4 purchased Series A Convertible Preferred Stock and a Common Stock Purchase Warrant from Vivos Therapeutics, Inc. in a private placement on June 30, 2026.The total funds used for recent purchases amounted to $1,600,000, which included the conversion of a $1,100,000 Convertible Promissory Note dated May 7, 2026.

Summary

V-CO Investors LLC, V-Co Investors 2 LLC, V-Co Investors 3 LLC, V-Co Investors 4 LLC, SP Manager LLC, and Michael C. Skaff have collectively disclosed beneficial ownership of 2,783,102 shares of Vivos Therapeutics, Inc. common stock, representing 19.9% of the outstanding shares.
This disclosure is made following a private placement transaction on June 30, 2026, where V-Co 4 purchased Series A Convertible Preferred Stock and a Common Stock Purchase Warrant.
The total funds used for these recent acquisitions amounted to $1,600,000, which included the conversion of a $1,100,000 Convertible Promissory Note dated May 7, 2026.
The reporting persons intend to engage in discussions with Vivos Therapeutics' management and board regarding financial performance, strategic direction, operations, and corporate governance.
Beneficial ownership percentages are calculated based on 13,894,600 shares outstanding as of May 20, 2026, plus shares issuable from certain securities held by V-Co Investors 4 LLC, subject to beneficial ownership limitations.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, primarily reporting on ownership changes and investment activities without immediate financial performance indicators or significant strategic shifts.

Positives

The reporting persons have acquired a substantial stake, indicating confidence or strategic interest in Vivos Therapeutics.
A recent private placement of $1,600,000, including conversion of a promissory note, has been completed.
The reporting persons intend to engage in discussions to potentially improve the company's performance and governance.

Negatives

The beneficial ownership is subject to a 19.99% limitation, meaning the full potential ownership from acquired securities is capped.
The disclosure does not detail the specific outcomes of any discussions with the issuer's management or board.

Risks

Potential for future disagreements or conflicts with Vivos Therapeutics' management or board regarding strategic direction or governance.
The beneficial ownership limitation of 19.99% restricts the ability to increase the stake further through exercise of all convertible securities and warrants.

Future Outlook

The reporting persons intend to engage in discussions with the Issuer and its management and/or board of directors regarding the Issuer's financial performance, strategic direction, operational matters, and corporate governance practices. No specific future plans or proposals beyond these discussions are disclosed.

Management Comments

Each Reporting Person disclaims beneficial ownership with respect to any Shares other than the Shares directly beneficially owned by such Reporting Person, and to the extent of their pecuniary interest therein.
The Reporting Person's purpose of acquiring these securities is for investment purposes.
The Reporting Persons do not have any current plans or proposals which relate to, or would result in, any extraordinary corporate transaction, sale of assets, changes in board or management, material changes in capitalization or dividend policy, or other material changes to the Issuer's business or corporate structure.

Industry Context

StockSavvy.ai notes that significant stake acquisitions and subsequent engagement with management are common strategies for activist investors or strategic partners seeking to influence corporate direction, particularly in sectors undergoing rapid change or consolidation.

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Engagement on Governance	Reporting persons intend to engage with the Issuer's board of directors regarding corporate governance practices.	Ongoing	Potential for future changes or recommendations regarding corporate governance policies.

Stakeholder Impact

Shareholders: Potential for increased scrutiny on company performance and governance due to the significant stake held by the reporting persons.
Management/Board: Will likely engage in discussions with the reporting persons regarding company strategy and operations.
Creditors: No direct impact indicated, but changes in strategic direction could indirectly affect financial stability.

Next Steps

Engage in discussions with Vivos Therapeutics' management and board of directors regarding financial performance, strategic direction, operational matters, and corporate governance practices.

Key Dates

Date	Description
2024-07-30	Filing date of Issuer's Registration Statement on Form S-3, referencing Pre-Funded Warrant and Warrant issued to V-CO Investors LLC.
2025-06-09	Date of Pre-Funded Warrant and Common Stock Purchase Warrant issued to V-Co 2, referenced in Issuer's Form 8-K filed June 13, 2025.
2026-03-31	Date of Pre-Funded Warrant, Series A Common Stock Purchase Warrant, and Series B Common Stock Purchase Warrant issued to V-Co 3, referenced in Issuer's Form 8-K filed April 3, 2026.
2026-05-07	Date of Convertible Promissory Note between Issuer and V-Co 4.
2026-05-20	Date of Issuer's Quarterly Report on Form 10-Q, reporting 13,894,600 shares of Common Stock outstanding.
2026-06-30	Date of Securities Purchase Agreement between Issuer and V-Co 4 for Series A Convertible Preferred Stock and Common Stock Warrant.
2026-07-07	Filing date of Issuer's Current Report on Form 8-K, referencing Common Stock Warrant between the Company and V-Co 4.
2026-07-15	Date of the Schedule 13D filing and Joint Filing Agreement.

Recommendation

hold

The filing indicates a significant investment and intent to engage with management, suggesting a belief in the company's potential. However, without specific financial performance data or clear strategic initiatives outlined, a 'hold' recommendation is prudent, pending further developments from the engagement.

Keywords

Vivos Therapeutics, Schedule 13D, Beneficial Ownership, V-CO Investors LLC, SP Manager LLC, Michael C. Skaff, Private Placement, Convertible Preferred Stock

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.